Tags

Type your tag names separated by a space and hit enter

Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus.
Am J Physiol Endocrinol Metab. 2002 May; 282(5):E1154-62.AJ

Abstract

Abnormal lipid metabolism may be related to the increased cardiovascular risk in type 1 diabetes. Secretion and clearance rates of very low density lipoprotein (VLDL) apolipoprotein B100 (apoB) determine plasma lipid concentrations. Type 1 diabetes is characterized by increased growth hormone (GH) secretion and decreased insulin-like growth factor (IGF) I concentrations. High-dose IGF-I therapy improves the lipid profile in type 1 diabetes. This study examined the effect of low-dose (40 microg.kg(-1).day(-1)) IGF-I therapy on VLDL apoB metabolism, VLDL composition, and the GH-IGF-I axis during euglycemia in type 1 diabetes. Using a stable isotope technique, VLDL apoB kinetics were estimated before and after 1 wk of IGF-I therapy in 12 patients with type 1 diabetes in a double-blind, placebo-controlled trial. Fasting plasma triglyceride (P < 0.03), VLDL-triglyceride concentrations (P < 0.05), and the VLDL-triglyceride-to-VLDL apoB ratio (P < 0.002) significantly decreased after IGF-I therapy, whereas VLDL apoB kinetics were not significantly affected by IGF-I therapy. IGF-I therapy resulted in a significant increase in IGF-I and a significant reduction in GH concentrations. The mean overnight insulin concentrations during euglycemia decreased by 25% after IGF-I therapy. These results indicate that low-dose IGF-I therapy restores the GH-IGF-I axis in type 1 diabetes. IGF-I therapy changes fasting triglyceride concentrations and VLDL composition probably because of an increase in insulin sensitivity.

Authors+Show Affiliations

Department of Endocrinology and Diabetology of the Adult, University Hospital of Bern, Inselspital, CH-3010 Bern, Switzerland. Emanuel.Christ@insel.chNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11934682

Citation

Christ, Emanuel R., et al. "Effect of IGF-I Therapy On VLDL Apolipoprotein B100 Metabolism in Type 1 Diabetes Mellitus." American Journal of Physiology. Endocrinology and Metabolism, vol. 282, no. 5, 2002, pp. E1154-62.
Christ ER, Carroll PV, Albany E, et al. Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;282(5):E1154-62.
Christ, E. R., Carroll, P. V., Albany, E., Umpleby, A. M., Lumb, P. J., Wierzbicki, A. S., Sönksen, P. H., & Russell-Jones, D. L. (2002). Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. American Journal of Physiology. Endocrinology and Metabolism, 282(5), E1154-62.
Christ ER, et al. Effect of IGF-I Therapy On VLDL Apolipoprotein B100 Metabolism in Type 1 Diabetes Mellitus. Am J Physiol Endocrinol Metab. 2002;282(5):E1154-62. PubMed PMID: 11934682.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. AU - Christ,Emanuel R, AU - Carroll,Paul V, AU - Albany,Elaine, AU - Umpleby,A Margot, AU - Lumb,Peter J, AU - Wierzbicki,Anthony S, AU - Sönksen,Peter H, AU - Russell-Jones,David L, PY - 2002/4/6/pubmed PY - 2002/5/17/medline PY - 2002/4/6/entrez SP - E1154 EP - 62 JF - American journal of physiology. Endocrinology and metabolism JO - Am J Physiol Endocrinol Metab VL - 282 IS - 5 N2 - Abnormal lipid metabolism may be related to the increased cardiovascular risk in type 1 diabetes. Secretion and clearance rates of very low density lipoprotein (VLDL) apolipoprotein B100 (apoB) determine plasma lipid concentrations. Type 1 diabetes is characterized by increased growth hormone (GH) secretion and decreased insulin-like growth factor (IGF) I concentrations. High-dose IGF-I therapy improves the lipid profile in type 1 diabetes. This study examined the effect of low-dose (40 microg.kg(-1).day(-1)) IGF-I therapy on VLDL apoB metabolism, VLDL composition, and the GH-IGF-I axis during euglycemia in type 1 diabetes. Using a stable isotope technique, VLDL apoB kinetics were estimated before and after 1 wk of IGF-I therapy in 12 patients with type 1 diabetes in a double-blind, placebo-controlled trial. Fasting plasma triglyceride (P < 0.03), VLDL-triglyceride concentrations (P < 0.05), and the VLDL-triglyceride-to-VLDL apoB ratio (P < 0.002) significantly decreased after IGF-I therapy, whereas VLDL apoB kinetics were not significantly affected by IGF-I therapy. IGF-I therapy resulted in a significant increase in IGF-I and a significant reduction in GH concentrations. The mean overnight insulin concentrations during euglycemia decreased by 25% after IGF-I therapy. These results indicate that low-dose IGF-I therapy restores the GH-IGF-I axis in type 1 diabetes. IGF-I therapy changes fasting triglyceride concentrations and VLDL composition probably because of an increase in insulin sensitivity. SN - 0193-1849 UR - https://www.unboundmedicine.com/medline/citation/11934682/Effect_of_IGF_I_therapy_on_VLDL_apolipoprotein_B100_metabolism_in_type_1_diabetes_mellitus_ L2 - https://journals.physiology.org/doi/10.1152/ajpendo.00470.2001?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -